Ibogaine: FDA seeks to speed psychedelics research

Clinical takeaway: Tell patients who ask about ibogaine that research is only starting, with FDA still weighing cardiac and neurologic monitoring as well as a capped starting dose. 

People with opioid use disorder (OUD) or post-traumatic stress disorder (PTSD) are seeking out ibogaine, a psychedelic with a documented cardiac hazard. Health and Human Services has named adults with those two conditions as the first groups for federally supported research. 

Previously, FDA declined to approve MDMA-assisted therapy for PTSD in 2024. Ahead of that decision, FDA staff concluded that patients and therapists likely knew who had received the drug. Reviewers added that the effect of that knowledge on the research outcomes could not be quantified. Guidance finalized in July steers sponsors toward alternatives to an inert placebo and toward results strong enough to hold up despite unblinding. FDA ties the new request for information to an April 2026 executive order directing agencies to accelerate psychedelic research. The request looks to clarify what's needed in ibogaine's first human studies, asking how they should handle dosing, monitoring, and oversight. 

FDA is seeking comment on four areas of early-phase ibogaine trials: study design, dose escalation, safety, and ethical oversight. For dosing, the agency is considering small groups that receive escalating doses in sequence, starting at a level justified by available data and no higher than 10 mg/kg. Monitoring would focus on cardiac and neurologic adverse events. FDA also asks about care setting, eligibility criteria, and stopping rules. A study of 14 patients with OUD who received 10 mg/kg, the ceiling FDA is considering for starting doses, found a reversible lengthening of the heart rate-corrected QT interval, plus bradycardia and severe ataxia. 

The agency wants input on informed consent and independent safety oversight, with the 10 mg/kg ceiling, the dosing design, and the monitoring plan all open to comment. 

The request for information lays out protocol approaches FDA is considering for early-phase ibogaine trials. Stakeholders can submit comments, data, and supporting information to a public docket. 

The comment window closes Friday, Nov. 20, 2026, and late submissions won't be considered. The Advanced Research Projects Agency for Health (ARPA-H) is funding early-phase trials to collect safety and efficacy data, and the National Institute on Drug Abuse is backing ibogaine research for OUD. The April executive order directs HHS and FDA to work with the Department of Veterans Affairs to increase trial participation, data sharing, and real-world evidence on psychedelic drugs. FDA has also allowed a study of noribogaine, an ibogaine derivative, to proceed as a potential treatment for alcohol use disorder. Schedule I status complicates ibogaine research, since trials must also meet DEA requirements for manufacturing, importation, handling, and storage of the drug. 

Other psychedelics have reached phase 3, among them psilocybin and lysergide (LSD). Psilocybin for treatment-resistant depression has succeeded in two phase 3 trials; FDA has agreed to review its application on a rolling basis and selected it for a priority voucher program designed to shorten review to one to two months once the application is filed. LSD for generalized anxiety disorder and major depressive disorder has posted positive results in three phase 3 trials and the anxiety program has carried a breakthrough therapy designation since 2024. 

"Patients facing serious conditions that have not responded to existing treatments deserve rigorous scientific investigation of promising new approaches," said Michael Davis, M.D., Ph.D., director of the FDA Center for Drug Evaluation and Research. "With ibogaine, there are important scientific questions as well as serious safety concerns. We are seeking high-quality data and input that can help inform clinical research while putting patient safety first." 

Source: Food and Drug Administration (2026 Oct 5) FDA news release. FDA seeks public input to support ibogaine research